Speciality Medicines Ltd IPO

Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceutical products used in the treatment of complex and chronic medical conditions. These products are primarily used in therapeutic areas such as oncology, immunology, neurology, and rare diseases. The company offers a portfolio of speciality medicines available in multiple dosage forms, including tablets, capsules, syrups, injections, infusions, inhalers, creams, gels, ointments, eye drops, nasal sprays, oral solutions, and suspensions. Its operations follow two integrated models: contract manufacturing of approved finished formulations through third-party manufacturers in India for international distribution and marketing and distribution of speciality pharmaceutical products sourced from manufacturers. Under the distribution model, the company handles procurement, warehousing, and wholesale supply of medicines to healthcare providers and retailers. As of March 31, 2025, the company’s portfolio included more than 900 products, and its distribution network covered more than 20 states in India and over 35 countries globally.;